Replies to post #191444 on Biotech Values

[biomaven0]

>>It's much easier to approximate ENTA's market with a "X HCV patients x Y% penetrance x $Z cost = revenue" formula than it is roxa's

And what number do you plan to use for "Y" that makes this easier?

Peter